PolyPid is a global clinical-stage bio-pharmaceutical company that is dedicated to enhancing surgical outcomes through the development, manufacturing, and commercialization of innovative, locally administered therapies. Their groundbreaking PLEX (Polymer-Lipid Encapsulation matriX) technology serves as a unique platform, providing controlled and continuous delivery of medications at the surgical site. By delivering medication directly to the surgical site, PolyPid's product candidates aim to improve patient outcomes for localized medical conditions such as infection, pain, inflammation, and cancer over extended periods of time.

The company's initial focus is on preventing Surgical Site Infections (SSIs), which are among the most prevalent types of Healthcare Acquired Infections (HAIs) and have a significant impact on both patients and the healthcare system. PolyPid's strategy includes the development of their proprietary product pipeline as well as collaborations with pharmaceutical companies to optimize the local delivery of their medications. With their advanced targeted drug delivery platform, PolyPid is revolutionizing surgical care and striving to combat antibiotic-resistant bacteria, a major global public health concern